As shown in Figure 6A, PD-1 blockade potentiated the therapeutic efficacy of genetically modified B-cells, where a slight increase in antigen-specific CD8 T-cells was observed from peripheral blood samples on day 32 post-tumor inoculation (data not shown). Here, CD8A is linked to neoplasm.